Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -383% Improvement Relative Risk Ventilation -37% Time to improvement 0% no CI Dischage or NEWS <3 17% Time to viral- -125% Favipiravir  FAVID  LATE TREATMENT  DB RCT Is late treatment with favipiravir beneficial for COVID-19? Double-blind RCT 44 patients in Spain (November 2020 - October 2021) Higher mortality (p=0.49) and slower viral clearance (p=0.51), not sig. Horcajada et al., Research Square, Aug 2023 Favors favipiravir Favors control

Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)

Horcajada et al., Research Square, doi:10.21203/, FAVID, EudraCT2020-002753-22
Aug 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Underpowered RCT with 44 hospitalized patients in Spain, showing no significant difference with favipiravir treatment in the primary outcome of time to clinical improvement, or in the secondary efficacy outcomes. Adverse events were more frequent in the favipiravir group (68%) compared to placebo (32%), but most were mild.
risk of death, 382.6% higher, RR 4.83, p = 0.49, treatment 2 of 23 (8.7%), control 0 of 21 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.
risk of mechanical ventilation, 37.0% higher, RR 1.37, p = 1.00, treatment 3 of 23 (13.0%), control 2 of 21 (9.5%), day 28.
time to improvement, no change, relative time 1.00, p = 0.45, treatment 23, control 21.
dischage or NEWS <3, 16.7% lower, relative time 0.83, p = 0.64, treatment 23, control 21.
time to viral-, 125.0% higher, relative time 2.25, p = 0.51, treatment 23, control 21.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Horcajada et al., 24 Aug 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, preprint, 14 authors, study period November 2020 - October 2021, trial EudraCT2020-002753-22 (FAVID).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Juan P Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran Taberna, Andrés Fernández, Cristina Tarragó, Teresa Auguet Quintillá
Purpose: To design a randomized clinical trial to assess the e cacy and safety of favipiravir in patients with COVID-19 disease with pneumonia. Methods: A randomized, double blind, placebo-controlled clinical trial of favipiravir in patients with COVID-19 pneumonia was conducted in 3 Spanish sites. Randomization 1:1 to favipiravir or placebo (in both groups added to the Standard of Care) was performed to treat the patients with COVID-19 pneumonia. The primary endpoint was "time to clinical improvement," measured as an improvement for ≥ two categories on a 7-point WHO ordinal scale in an up to 28 days' time frame. Results: 44 patients were randomized (23 in the favipiravir group and 21 in the placebo group). The median time to clinical improvement was not different between the favipiravir and the placebo arms (10 days for both groups) and none of the secondary endpoints showed signi cant differences between arms. The proportion of adverse events (both serious and non-serious) was statistically different between the favipiravir group (68.29%) and the placebo group (31.7%) (p = 0.019), but there was insu cient statistical evidence to correlate the degree of severity of the events with the treatment groups. Conclusions: Favipiravir administered for ten days to patients with COVID-19 and pneumonia did not improve outcomes compared with placebo. Although this is an underpowered negative study, e cacy results align with other randomized trials. However, in the present study, the non-serious adverse events were more frequent in the favipiravir group.
Acanfora, Acanfora, Ciccone, Scicchitano, Bortone et al., The Cross-Talk between Thrombosis and In ammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases, Viruses, doi:10.3390/v13101904
Alqahtani, Kumar, Aljawder, Abdulrahman, Mohamed et al., Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease, Sci Rep, doi:10.1038/s41598-022-08794-w
Bai, Mu, Od, Song, Niuwk et al., Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, Clin Infect Dis
Beigel, Tomashek, Dodd, Mehta, Zingman et al., ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bosaeed, Alharbi, Alrehily, Bahlaq, Gaifer, E cacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial, Clin Microbiol Infect, doi:10.1016/j.cmi.2021.12.026
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing), doi:10.1016/j.eng.2020.03.007
Chuah, Chow, Hor, Cheng, Ker et al., Malaysian Favipiravir Study Group. E cacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial, Clin Infect Dis, doi:10.1093/cid/ciab962
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, doi:10.1016/j.antiviral.2013.09.015
Gowen, Wong, Jung, Sanders, Mendenhall et al., In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections, Antimicrob Agents Chemother
Gök, Bahçecioğlu, Durmuş, Gün, Ersoy et al., The safety pro le of favipiravir in COVID-19 patients with severe renal impairment, Int J Clin Pract, doi:10.1111/ijcp.14938
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The e cacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.Sci Rep, doi:10.1038/s41598-021-90551-6
Horby, Lim, Emberson, Mafham, Bell et al., RECOVERY Collaborative Group. Dexametasona en pacientes hospitalizados con Covid-19, doi:10.1056/NEJMoa2021436
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069
Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis, doi:10.1186/s12879-021-06164-x
Marconi, Ramanan, De Bono, Kartman, Krishnan et al., COV-BARRIER Study Group. E cacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial, Lancet Respir Med, doi:10.1016/S2213-2600(21)00331-3
Mcelvaney, Nalbandian, Sehgal, Gupta, Madhavan et al., Post-acute COVID-19 syndrome, Nat Med, doi:10.1038/s41591-021-01283-z
Mcmahon, Lau, Coldham, Roney, Hagenauer et al., Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial, EClinicalMedicine, doi:10.1016/j.eclinm.2022.101703
Meyerowitz, Richterman, Gandhi, Transmission of SARS-CoV-2: a review of viral host, and environmental factors, Ann Intern Med
Nalbandian, Sehgal, Gupta, Madhavan, Mcgroder et al., Post-acute COVID-19 syndrome, Nat Med, doi:10.1038/s41591-021-01283-z
Oestereich, Lüdtke, Wur Rs, Rieger, Riegert et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Ozsurekci, Oygar, Gürlevik, Kesici, Ozen et al., Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? Pediatr Nephrol, doi:10.1007/s00467-021-05111-x
Peiffer-Smadja, Rebeaud, Guihur, Mahamat-Saleh, Fiolet, Hydroxychloroquine and COVID-19: a tale of populism and obscurantism, Lancet Infect Dis, doi:10.1016/S1473-3099
Schumaker, Bhimraj, Pharmacologic Treatment and Management of Coronavirus Disease, Infect Dis Clin North Am, doi:10.1016/j.idc.2022.02.001
Shah, Orton, Grinsztejn, Donaldson, Ramírez et al., Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care, Lancet Respir Med, doi:10.1016/S2213-2600(22)00412-X
Shankar-Hari, Vale, Godolphin, Fisher, Higgins et al., Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis, JAMA, doi:10.1001/jama.2021.11330
Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., E cacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial, Infect Dis Ther, doi:10.1007/s40121-021-00517-4
Sirijatuphat, Manosuthi, Niyomnaitham, Owen, Copeland et al., Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study, Emerg Microbes Infect, doi:10.1080/22221751.2022.2117092
Sussman, Golberstein, Polosa, Aerial Transmission of the SARS-CoV-2 Virus through Environmental E-Cigarette Aerosols: Implications for Public Policies, Int J Environ Res Public Health, doi:10.3390/ijerph18041437
Udwadia, Singh, Barkate, Patil, Rangwala et al., E cacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis
Ueda, Tanimoto, Murayama, Ozaki, Kami, Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir, Clin Pharmacol Ther, doi:10.1002/cpt.2251
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Research
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop